Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Jul;33(7):1503-8.
doi: 10.2337/dc09-2009. Epub 2010 Mar 23.

Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes

J Michael Gaziano  1 , Anthony H Cincotta, Christopher M O'Connor, Michael Ezrokhi, Dean Rutty, Z J Ma, Richard E Scranton
Affiliations
Randomized Controlled Trial

Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes

J Michael Gaziano et al. Diabetes Care. 2010 Jul.

Erratum in

Abstract

Objective: Quick-release bromocriptine (bromocriptine-QR), a D2 dopamine receptor agonist, is indicated as a treatment for type 2 diabetes. The Cycloset Safety Trial, a 52-week, randomized, double-blind, multicenter trial, evaluated the overall safety and cardiovascular safety of this novel therapy for type 2 diabetes.

Research design and methods: A total of 3,095 patients with type 2 diabetes were randomized 2:1 to bromocriptine-QR or placebo in conjunction with the patient's usual diabetes therapy (diet controlled only or up to two antidiabetes medications, including insulin). The all-cause-safety end point was the occurrence of any serious adverse event (SAE), with a hazard ratio (HR) noninferiority margin of 1.5. In a prespecified analysis, the frequency of cardiovascular disease (CVD) events defined as a composite of myocardial infarction, stroke, coronary revascularization, and hospitalization for angina or congestive heart failure was evaluated using modified intent-to-treat analysis (clinicaltrials.gov, NCT00377676).

Results: In the bromocriptine-QR group, 176 (8.6%) people reported SAEs compared with 98 (9.6%) in the placebo group (HR 1.02 [96% one-sided CI 1.27]). Fewer people reported a CVD end point in the bromocriptine-QR group versus the placebo group (37 [1.8%] vs. 32 [3.2%], respecively) (HR 0.60 [95% two-sided CI 0.35-0.96]). Nausea was the most commonly reported adverse event in the bromocriptine-QR group.

Conclusions: The frequency of SAEs was comparable between the treatment arms. Compared with patients in the placebo arm, fewer patients taking bromocriptine-QR experienced a cardiovascular end point.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier curve of the occurrence of the prespecified composite cardiovascular end point among patients randomized to bromocriptine-QR or placebo. The composite cardiovascular end point consisted of the time to first myocardial infarction, stroke, coronary revascularization, hospitalization for unstable angina, or hospitalization for congestive heart failure that occurred after randomization. All cardiovascular events were independently adjudicated. The hazard ratio of bromocriptine-QR versus placebo for the occurrence of the composite cardiovascular end point was 0.60 (95% CI 0.37–0.96). The effect of treatment was estimated from the unadjusted Cox proportional-hazard model that used all the available data.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, Connolly V, King H: The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005; 28: 2130–2135 - PubMed
    1. Diabetes Facts and Figures. World Health Ogranization. Available from http://www.who.int/diabetes/facts/en/. Accessed
    1. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–2471 - PubMed
    1. Olsson J, Lindberg G, Gottsäter M, Lindwall K, Sjöstrand A, Tisell A, Melander A: Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 2000; 43: 558–560 - PubMed
    1. Walker AM, McAfee AT, Koro C: Studies of diabetes, thiazolidinediones, and coronary heart disease. Pharmacoepidemiol Drug Saf 2007; 16: 1313–1314 - PubMed

Publication types

Associated data

  NODES
admin 2
twitter 2